PACTR202607643375797招募中2 期
Comparing the Efficacy and Safety of the Standard 21-hour N-Acetylcysteine Regimen versus the Scottish and Newcastle Acetylcysteine Protocol (SNAP) 12-hour Regimen in Patients with Acute Paracetamol Toxicity. A randomizd controlled trial.
Self sponsor0 个研究点目标入组 142 人开始时间: 2025年11月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 142
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 6 Year(s) 至 12 Year(s)（—）
- 性别
- All
入选标准
- •Patients aged 12 years or older (male and female) presenting with acute paracetamol toxicity requiring N-acetylcysteine treatment as per national guidelines (e.g., TOXBASE criteria).
- •This includes patients admitted within 8 hours of a single acute paracetamol overdose, or presenting with a staggered overdose or uncertain time of ingestion requiring NAC.
排除标准
- •patients aged less than 12 years old
- •2- known hypersensitivity or contraindication to N-acetylcysteine
- •3-individuals with pre-existing severe liver disease (e.g., cirrhosis, chronic liver failure) or other chronic comorbidities that may confound liver function assessment (e.g., chronic kidney disease, severe cardiovascular disease, diabetes, chronic pulmonary disease).
研究者
相似试验
招募中
不适用
An Exploratory Study of novel diuretic therapy for cirrhotic ascitesLiver cirrhosis with uncontrolled ascites complicated by Type 2 diabetes mellitusjRCT103125078610
招募中
1 期
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants with Advanced Solid Malignancies2024-511453-22-00Kumquat Biosciences Inc.112
招募中
不适用
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease (J2A-MC-GZPR)Peripheral Arterial DiseasejRCT20312505701,205
招募中
2 期
A study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF plus lomustine in patients with glioblastoma at first progressionGlioblastoma2022-501822-39-00Philogen S.p.A.113
招募中
1 期
A study to evaluate the safety and tolerability of single ascending doses of AGMB-101 in healthy participants (Part A) and patients with liver cirrhosis (Part B).2024-515074-26-00AgomAb Therapeutics64